Sonablate
Charlotte, US · Founded 2021 · Delaware corporation
Sonablate Corp. develops HIFU (high-intensity focused ultrasound) technology for focal therapy, initially applied to treating prostate disease as an alternative to conventional treatments. Its systems are used by physicians, with plans to address a broader range of medical conditions.
Founders & leadership
TM
Thomas MendellNamed on SEC filing
RS
Ralph SeipNamed on SEC filing
LT
Louis TaNamed on SEC filing
RY
Richard YangNamed on SEC filing
HW
Hong WeiNamed on SEC filing
NS
Neal SanganiNamed on SEC filing
AG
Alejandro GonzalezNamed on SEC filing
BM
Bruce MurphyNamed on SEC filing
SP
Samuel PeretsmanNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$377K disclosed across 1 round · 2023
▶$377KraisedAug 2023 · 6 investors · BiotechnologyRule 506(b)
▶$377KraisedAug 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas MendellDirector
- Ralph SeipExecutive Officer
- Louis TaExecutive Officer
- Richard YangExecutive Officer, Director
- Hong WeiDirector
- Neal SanganiDirector
- Alejandro GonzalezExecutive Officer, Director
- Bruce MurphyDirector
- Samuel PeretsmanDirector
- Offering amount
- $60M
- Amount sold
- $377K
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Sonablate do?
- Sonablate Corp. develops HIFU (high-intensity focused ultrasound) technology for focal therapy, initially applied to treating prostate disease as an alternative to conventional treatments. Its systems are used by physicians, with plans to address a broader range of medical conditions.
- How much funding has Sonablate raised?
- Sonablate has disclosed $377K raised across 1 round.
- Where is Sonablate headquartered?
- Sonablate is headquartered in Charlotte, US.